Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-2001 is a long-acting veterinary drug candidate developed by G2G Bio for chemical castration in animals. It is formulated as a sustained-release injection using G2G Bio's proprietary InnoLAMP (Innovative Long-Acting MicroParticle) technology, which utilizes biodegradable polymer microspheres to provide a therapeutic duration of six months. The drug contains a gonadotropin-releasing hormone (GnRH) agonist, likely leuprolide acetate, which works by continuously stimulating the GnRH receptors in the pituitary gland. This continuous stimulation leads to receptor downregulation and a subsequent decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), effectively suppressing the production of sex steroids (testosterone in males) to achieve non-surgical castration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GB-2001.